Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

CAMBRIDGE, England, November 21, 2011 /PRNewswire/ --

Phase I Single Dose Study Data Demonstrate Ideal Pharmacokinetic Profile and Excellent Safety and Tolerability

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

The trial is a randomised, placebo controlled Phase I study to investigate the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944 in both young and elderly volunteers. CNV2197944 is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis. The study is expected to conclude in 2Q 2012.

The first human single ascending dose Phase I study with orally administered CNV2197944 was recently completed. CNV2197944 was shown to be well absorbed, with an ideal pharmacokinetic profile for the target indication of chronic pain. The compound was well tolerated, with an excellent safety profile.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, commented: "We are really excited to be advancing on schedule to a multiple ascending dose study with this novel, first-in-class treatment for chronic pain.  The data we have seen so far gives us great confidence that CNV2197944 will be a safe and effective long term treatment for chronic pain."

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015  CytomX, a biotechnology company developing ... announced the appointments of Bob Goeltz ... as senior vice president and general counsel. ... officer of Onyx Pharmaceuticals, an Amgen subsidiary. Ms. ... legal counsel to several leading biotech companies, including ...
(Date:5/27/2015)... NEW YORK , May 27, 2015  US-Australian drug ... NVGN ), announced today that it will present at the ... New York on May 29, 2015. The venue ... Manhattan . The Brain ... biotechnology companies, the pharmaceutical industry and the investment community to ...
(Date:5/26/2015)... and BELLINGHAM, Washington, USA (PRWEB) May 26, 2015 ... signed a formal partnership with the Max Planck ... for Extreme and Quantum Photonics. The center will link ... field of photonics, and will be only the third ... of SPIE, the international society for optics and ...
(Date:5/26/2015)... Kalifornien und HILDEN, Deutschland, May 26, 2015 ... Insight ®   ermöglicht ... die Erstellung dazugehöriger Berichte; Vorstellung auf den ... QIAGEN N.V. (NASDAQ: QGEN ; ... Markteinführung von QIAGEN Clinical Insight ® ...
Breaking Biology Technology:CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6
... BEIJING, April 11, 2011 /PRNewswire-Asia/ -- Chinmax Medical Systems ... an update regarding the progress of its lawsuit against ... ALR). According to the Complaint, Inverness ... and sold the same to Chinmax customers during the ...
... Omeros Corporation (NASDAQ: OMER ), a biopharmaceutical ... on inflammation, bleeding and disorders of the central nervous ... and chief executive officer, is scheduled to present at ... Conference.  The presentation is scheduled for Friday, April 15, ...
... electronic age rests on our ability to control how ... through circuitry. Doing so requires particular precision, for applications ... that task falls to semiconductors. Now, a research ... and Applied Science and Arts and Sciences has shown ...
Cached Biology Technology:Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc. 2Penn research advances understanding of lead selenide nanowires 2Penn research advances understanding of lead selenide nanowires 3
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... JOLLA, Calif., April 8, 2009 -- Investigators at Burnham ... percentage of the total protein complement (proteome) in ... Laurence Brill, Khatereh Motamedchaboki, Ph.D. and lead investigator ... identify 4,600 proteins in the organism, using an array ...
... a letter recently sent to President Obama, more than ... education communities, lauded the President for his outstanding leadership ... education. Read the letter below. Dear Mr. ... scientific, and higher education communities, we wish to commend ...
... (BRONX, NY) Scientists at Albert Einstein College of Medicine ... sensitive test to detect and quantify ricin, an extremely potent ... appears as a featured article in the April 12th issue ... from castor beans, can be in the form of a ...
Cached Biology News:Business, scientific, higher education groups laud President Obama's commitment to science 2Einstein researchers devise a fast and sensitive way to detect ricin 2